Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension.
Howes
L
L
D000368:Aged; D006328:Cardiac Catheterization / Q000009:adverse effects*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004110:Diltiazem / Q000494:pharmacology*; D004347:Drug Interactions; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D007022:Hypotension / Q000209:etiology*; D008297:Male; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D009566:Nitrates / Q000009:adverse effects; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics*; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D002317:Cardiovascular Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D009566:Nitrates; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D004110:Diltiazem